Menu
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com
NovoCure focuses on promoting Optune and Optune Lua, utilizing TTFields technology to target and destroy cancer cells. See why we recommend a buy on NVCR stock.
https://www.investing.com/news/pro/jpmorgan-downgrades-novocure-ltd-to-underweight-432SI-3033169
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
Canada Pension Plan Investment Board trimmed its position in shares of NovoCure Limited by 52.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 823 shares of…
Novocure (NVCR) said its device Optune will get reimbursement and was available with temozolomide ((TMZ)) in France to treat adult patients with newly diagnosed glioblastoma ((GBM)),…
Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating…
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28, 2023 and will become effective March 15, 2023. "We are pleas
Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February
Benzinga Pro data, NovoCure (NASDAQ: NVCR ) reported Q4 sales of $128.43 million. Earnings fell to a loss of $37.30 million, resulting in a 40.36% decrease from last quarter. NovoCure collected $131.00 million in revenue during Q3, but reported earnings showed a $26.58 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Investors were looking for a stronger Q4 from the cancer company.
Novocure Limited (NASDAQ:NASDAQ:NVCR) Q4 2022 Results Earnings Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsIngrid Goldberg - Vice President of Investor RelationsWilliam…
NVCR earnings call for the period ending December 31, 2022.
The following slide deck was published by NovoCure Limited in conjunction with their 2022 Q4 earnings call.
ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $37.3…
NovoCure (NVCR) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open.The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate…
There was good news from the laboratory on Hump Day.
As of Thursday, NovoCure Limited’s (NASDAQ:NVCR) stock closed at $87.50, down from $90.13 the previous day. While NovoCure Limited has underperformed by -2.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVCR rose by 16.20%, with highs and lows ranging from $120.03 to $56.39, whereas the […]
NovoCure Limited recently generated stellar data for the Phase 3 (LUNAR) trial for non-small cell lung cancer. Click here for more on NVCR stock.
In last trading session, NovoCure Limited (NASDAQ:NVCR) saw 0.54 million shares changing hands with its beta currently measuring 0.78. Company’s recent per share price level of $90.90 trading at $0.85 or 0.94% at ring of the bell on the day assigns it a market valuation of $9.49B. That closing price of NVCR’s stock is at … NovoCure Limited (NASDAQ:NVCR) Has Reached A Distance Of 37.96% From Its Low, So Is It Poised For More Gains? Read More »